CytomX Therapeutics
CTMX
179 hedge funds and large institutions have $799M invested in CytomX Therapeutics in 2026 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 71 increasing their positions, 33 reducing their positions, and 45 closing their positions.
115% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 33
105% more call options, than puts
Call options by funds: $5.27M | Put options by funds: $2.57M
4% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 45
0% more funds holding
Funds holding: 179 → 179 (0)
12% less capital invested
Capital invested by funds: $908M → $799M (-$109M)
15.64% less ownership
Funds ownership: 113.5% → 97.86% (-16%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$47.1M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$25.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$23.2M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$18.6M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$19.1M |
| 2 |
JFG
Jefferies Financial Group
New York
|
-$14.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$8.77M |
| 4 |
Millennium Management
New York
|
-$7.54M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.79M |
CTMX Hedge Fund Activity: Q2 2026 in Review
179 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2026, worth a combined $799M — down 12% from $908M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new CTMX positions and 45 closed out — a net gain of 2 holders — while 71 added to existing stakes and 33 trimmed.
The largest buyer was BlackRock, adding an estimated $47.1M. The largest seller was VR Adviser, cutting an estimated $19.1M.
- 179 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $799M of CytomX Therapeutics stock for Q2 2026, down 12% quarter-over-quarter.
- 47 funds opened new CytomX Therapeutics positions in Q2 2026 and 45 closed out, a net change of +2 holders.
- The largest CytomX Therapeutics buyer in Q2 2026 was BlackRock, an estimated $47.1M added.
- The largest CytomX Therapeutics seller in Q2 2026 was VR Adviser, an estimated $19.1M sold.
Based on aggregated 13F filings for Q2 2026.